Pharnext SA

ACTIVE

Francewww.pharnext.comPublic11–50 employeesEstablished: 2007-04-01

Clinical Trials

9 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2007

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

81.8%

Phase 3

18.2%

Trial Status Distribution

Active, not recruiting

81.8%

Recruiting

9.1%

Withdrawn

9.1%

Clinical Trials

Trials sponsored by this organization (11)

An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Phase 1

Active, not recruiting

Jun 2017187 participants

An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Phase 1

Active, not recruiting

Mar 2017187 participants

An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Phase 1

Active, not recruiting

Feb 2017187 participants

International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Phase 1

Active, not recruiting

Dec 2015300 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations

Pharnext SA

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (11)

Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients

Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients

Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients

Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients

An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Approvals

News